Research programme: astrocyte-derived neurotrophic factors - MANF Therapeutics

Drug Profile

Research programme: astrocyte-derived neurotrophic factors - MANF Therapeutics

Alternative Names: AMRS-001; CDNF - MANF Therapeutics; Conserved dopaminergic neurotrophic factor; MANF; MANF-based therapeutics - MANF Therapeutics; Mesencephalic astrocyte-derived neurotrophic factor

Latest Information Update: 06 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amarantus Therapeutics; University of Miami
  • Developer Amarantus Bioscience Holdings; Generex Biotechnology Corporation; MANF Therapeutics
  • Class Antidementias; Antiparkinsonians; Cardiovascular therapies; Eye disorder therapies; Nerve growth factors; Recombinant proteins
  • Mechanism of Action Apoprotein inhibitors; Apoptosis inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa; Retinal vein occlusion
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetes mellitus; Glaucoma; Macular degeneration; Parkinson's disease; Retinal vein occlusion; Retinitis pigmentosa; Spinocerebellar degeneration; Stroke
  • Research Alzheimer's disease
  • No development reported Amyotrophic lateral sclerosis; Brain injuries; Ischaemic heart disorders

Most Recent Events

  • 01 Mar 2018 MANF Therapeutics has patent covering the use of MANF as a treatment for beta cell disorders, including Type-1 and Type-2 diabetes in USA
  • 01 Mar 2018 MANF Therapeutics announces intention to submit IND for Glaucoma and Retinitis pigmentosa in 2018
  • 01 Mar 2018 Pharmacodynamics data from a preclinical trial in Diabetes mellitus released by MANF Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top